Monopar Therapeutics (MNPR) Non Operating Investment Income (2023)

Monopar Therapeutics has reported Non Operating Investment Income over the past 1 years, most recently at $33645.0 for Q1 2023.

  • Non Operating Investment Income reached $33645.0 in Q1 2023 per MNPR's latest filing.
  • Across five years, Non Operating Investment Income topped out at $33645.0 in Q1 2023 and bottomed at $33645.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 235,807.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 230,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 Monopar Therapeutics 466.82 Mn 466.82 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 33,645.00
Mar 31, 2023 33,645.00